The Report CIS Insulin Market (Rapid Acting, Short Acting, Pre-Mixed, Long Acting,
Type I & II Diabetes, Analogs, Recombinant Insulin) Analysis And Segment
Forecasts To 2020
The CIS Insulin Market is expected to reach USD 3,008.5 million by 2020
growing at a CAGR of 15.0%, according to a new study by Grand View Research,
Inc. The presence of an extensive pipeline portfolio of products
exhibiting higher efficacies and their subsequent commercialization over the
next six years is expected to serve this market as a high impact rendering
driver. The introduction of government initiatives aimed at improving the
affordability of insulin via price reduction, such as the collaboration between
the government of Ukraine and Indar to reduce the price of insulin by 20% in
2013 is expected to have positive influence on demand. Some of the other
drivers of this market include increasing attempts made by manufacturers to
capitalize on the untapped opportunities by opening new manufacturing units to
improve the supply of insulin and growing incidence rates of type II diabetes
are some of the factors expected to fuel future market growth.
Access Research Report of CIS Insulin Market@ www.grandviewresearch.com/industry-analysis/cis-insulin-market
Further key findings from the study suggest:
· Regionally, Russia
occupied the largest share of the market, accounting for 69.2% of the revenue.
Its large share is majorly attributed by the subsidies that Russian government
provides to make insulin more affordable for patients.
· Ukraine is expected to
register the fastest CAGR of 15.6% during the forecast period due to the
presence of high untapped opportunities and encouraging government initiatives.
· In addition, Poland is
expected to grow at a lucrative rate during the forecast period majorly owing
to the presence of high diabetes prevalence coupled with increasing healthcare
expenditures.
· Long acting insulin
accounted for the largest share of the market, at over 39.0% in 2013, owing to
the higher preference given to long acting insulin therapy for diabetes which
results in lesser episodes of low blood sugar. It is also expected that this
product segment will grow at the fastest CAGR of over 18.0% during the next six
years.
· Application of insulin
for control of type II diabetes occupied for over 90.0% of the market owing to
the presence of larger portfolio of products catering to this segment and a
relatively larger prevalence base
· Analogs accounted for
over 80.0% of the revenue owing to their relatively higher prices and better
efficacy levels. In addition, this segment is expected to exhibit the fastest
CAGR during the forecast period on account of the introduction of
technologically advanced products such as ultra-long and ultra-fast acting
analogs.
Grand View Research has segmented the CIS Insulin market
on the basis of product, application, source and region:
CIS Insulin Product
Outlook
·
Rapid Acting
·
Long Acting
·
Premixed
·
Premixed Analog
·
Short Acting
·
Intermediate Acting
CIS Insulin Application
Outlook
·
Type II Diabetes
·
Type I Diabetes
CIS Insulin Source
Outlook
·
Human Recombinant
·
Analogs
CIS Insulin Regional
Outlook
·
Russia
·
Poland
·
Turkey
·
Ukraine
·
Uzbekistan
·
Belarus
·
Kazakhstan
·
Rest of CIS
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
